COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics. - Agarwal R; Green JB; Heerspink HJL; Mann JFE; McGill JB; Mottl AK; Rosenstock J; Rossing P; Vaduganathan M; Brinker M; Edfors R; Li N; et al. (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2025)